G

Grifols SA
D

GRFS

8.85500
USD
-0.12
(-1.34%)
مغلق
حجم التداول
0
الربح لكل سهم
1
العائد الربحي
-
P/E
33
حجم السوق
6,025,022,616
أصول ذات صلة
ALNY
ALNY
3.30
(1.08%)
308.00 USD
AMGN
AMGN
-2.10
(-0.70%)
295.22 USD
AZN
AZN
-0.575
(-0.77%)
74.425 USD
BMY
BMY
-0.910
(-1.80%)
49.760 USD
GSK
GSK
-1.630
(-3.84%)
40.840 USD
ICLR
ICLR
-1.330
(-0.90%)
145.720 USD
NVO
NVO
-1.210
(-1.49%)
79.850 USD
PFE
PFE
-0.315
(-1.27%)
24.535 USD
SNY
SNY
-1.170
(-2.30%)
49.680 USD
TAK
TAK
-0.165
(-1.07%)
15.205 USD
المزيد
الأخبار المقالات

العنوان: Grifols SA

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.